Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CP101 in Recurrent C. difficile Infection
NCT03110133Phase 2Completed
- Sponsor
- Finch Therapeutics
- Start
- May 2017
- Primary completion
- Feb 2020
- Modality
- Live Biotherapeutic Products
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in Clostridioides difficile infection (CDI) comparing CP101 with Placebo (2 arms). Primary endpoints: Number of Participants With Absence of Recurrence Through Week 8 Based on Adjudication and Number of Participants With Occurrence of Treatment Emergent Adverse Events at 8 weeks. Started May 2017; status: completed.
02
Drugs
CP101
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT03110133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03110133.